Repligen: Solid Execution and Credible Growth Outlook, But Upside Limited at Current Valuation

Canaccord Genuity analyst Kyle Mikson CFA maintained a Hold rating on Repligen yesterday and set a price target of $165.00.

Kyle Mikson CFA has given his Hold rating due to a combination of factors related to Repligen’s current performance and valuation. He acknowledges that recent quarterly results exceeded expectations, with broad-based revenue growth led by key franchises and solid margin execution, and he views the company’s 2026 revenue and profitability guidance as credible and indicative of potential outperformance versus the wider bioprocessing market.

At the same time, he sees the stock as already pricing in strong long-term growth and margin expansion, which limits upside from current levels. While he is encouraged by the company’s innovation pipeline, including chromatography resins and advanced process analytics technologies, he prefers more clarity on the durability of longer-term growth drivers before adopting a more constructive stance on the shares.

In another report released today, TipRanks – Google also downgraded the stock to a Hold with a $146.00 price target.